Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Rallybio Corporation - Common Stock
(NQ:
RLYB
)
0.9500
-0.0262 (-2.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rallybio Corporation - Common Stock
< Previous
1
2
3
4
5
6
Next >
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
December 10, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
December 02, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
November 27, 2024
From
Rallybio Corporation
Via
Business Wire
RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024
May 09, 2024
RLYB stock results show that Rallybio beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
November 26, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
November 25, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
November 21, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 07, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
October 29, 2024
From
Rallybio Corporation
Via
Business Wire
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
September 30, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
September 23, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
September 10, 2024
From
Rallybio Corporation
Via
Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
September 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
August 29, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences
August 27, 2024
From
Rallybio Corporation
Via
Business Wire
RLYB Stock Earnings: Rallybio Misses EPS for Q2 2024
August 08, 2024
RLYB stock results show that Rallybio missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
July 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
June 17, 2024
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 06, 2024
Via
Benzinga
3 Sorry Biotech Stocks to Sell in May While You Still Can
May 31, 2024
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell.
Via
InvestorPlace
3 Biotech Stocks to Sell in May Before They Crash & Burn
May 10, 2024
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
Via
InvestorPlace
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
May 07, 2024
From
Rallybio Corporation
Via
Business Wire
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
April 17, 2024
From
Rallybio Corporation
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 12, 2024
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 12, 2024
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
April 12, 2024
The weekly Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers. Here are this week's stocks to watch.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
April 12, 2024
Friday is here and we're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.